Top Stock Movers Today — July 13, 2026: Why SOBR, AGEN & ACTU Surged

SOBR — SOBR Safe, Inc. (+174.4%)

SOBR Safe, Inc. exploded 174.4% on Monday, closing at $1.19 on volume of 51,248,232 shares — a staggering 16x its 20-day average of roughly 3.2 million shares. With a market cap of just $1.2 million, this is one of the smallest names you'll ever see on a top-movers list, and that extreme illiquidity is exactly what can make moves this violent.

Why it moved: No specific catalyst was identified from live web research for Monday's session. The most recent corporate development on record is an SEC 8-K filed July 10 disclosing a restructuring — a filing that is typically considered event-neutral on its own. With no clear fundamental driver, this move appears to be momentum- and technically-driven, likely fueled by the stock's micro-float. A tiny float means that even a modest surge in buy orders can overwhelm available supply and send the price rocketing — a dynamic sometimes called a low-float squeeze (not to be confused with a short squeeze, which is driven specifically by short-sellers being forced to buy back shares).

From a technical standpoint, the day printed a bullish belt hold candlestick — a single-bar pattern where price opens near its low and closes near its high, signalling strong intraday buying pressure. RSI (Relative Strength Index, a 0–100 momentum gauge) closed at 61, not yet in overbought territory, while ADX at 18 suggests trend strength is still developing. The MA stack is mixed, and the stock remains 74.8% below its 52-week high despite the enormous single-day move. StockSetups assigned a conviction score of 38/100 and a grade of D — underscoring that the technical setup is weak outside of today's momentum burst. Reddit's r/pennystocks picked it up with minimal buzz (rank #110, 1 mention), suggesting this was not a crowdsourced pump at the time of the scan.

Risk flag: A $1.2M market cap, a restructuring overhang, and a 16x-average-volume candle with no confirmed catalyst are the hallmarks of extreme speculative risk. Moves like this in micro-cap names frequently reverse sharply within one to three sessions.

AGEN — Agenus Inc. (+82.1%)

Agenus surged 82.1% on Monday, closing at $6.10 on a remarkable 488,348,627 shares traded — nearly 19x its 20-day average of ~25.3 million. For a healthcare name with a $139.5M market cap, that kind of volume points to a major, confirmed catalyst drawing in both retail and institutional attention.

Why it moved: The catalyst here is clear and well-documented. Agenus secured a strategic financing package of up to $340 million — including an initial $85 million private placement — specifically to advance its colon cancer program, as reported by Advfn, TipRanks, Yahoo Finance, and GuruFocus. This type of large, structured financing deal signals that institutional backers have conviction in the underlying pipeline, which can rapidly reprice a biotech's equity. The deal removes near-term cash-runway uncertainty, a perennial concern for clinical-stage biotechs, and the colon cancer program in focus gives investors a specific, high-value indication to anchor expectations.

The gap-up at the open was enormous: StockSetups logged the stock gapping +60.8% from the prior close — meaning Agenus opened the day already up more than half before a single share changed hands in regular trading. A gap is when a stock opens meaningfully above (or below) its prior close, leaving a blank space on the chart. From there, buyers continued to push the stock higher through the session. RSI closed at 83 — solidly in overbought territory (readings above 70 traditionally signal the stock has risen quickly and may be due for a pause or pullback; see our piece on bearish divergence and RSI for what to watch next). The stock sits just 13.6% below its 52-week high, meaning it is now one of the closest-to-highs names on the day's board. Technical rank hit 96/100, and the conviction score came in at 47/100 with a grade of C — decent for a news-driven biotech gap.

Risk flag: Financing deals can be dilutive to existing shareholders depending on structure, and biotech stocks frequently give back a significant portion of a news-driven surge as traders who bought the gap look to lock in profits. RSI at 83 leaves little technical margin for error.

ACTU — Actuate Therapeutics, Inc. (+24.4%)

Actuate Therapeutics closed up 24.4% at $1.50 on 22,099,768 shares — roughly 16x its 20-day average of ~1.3 million. The company is a clinical-stage healthcare name with a market cap of $29.7 million, putting it firmly in speculative small-cap territory.

Why it moved: Actuate was cited in Benzinga's intraday roundup of healthcare stocks on the move (July 13), but no specific press release, SEC filing, trial result, or partnership announcement was surfaced by web research as the driver. With no pinned fundamental catalyst, this move looks primarily momentum-driven, possibly lifted by the broader healthcare tape — Agenus's massive financing deal can sometimes pull sympathetic buying into nearby small-cap biotech and pharma names as traders hunt for the next mover in the sector.

The technical picture is notably weak outside of today's volume surge. The MA (moving average) stack is bearish — meaning shorter-term averages are trading below longer-term ones, a sign the underlying trend has been down. The stock is 82.7% below its 52-week high, and the Minervini trend-template score is 0 — the lowest possible reading in StockSetups' trend-quality ranking. RSI at 42 is neither overbought nor oversold. The day did print a bullish belt hold candle (open near the low, close near the high), mirroring SOBR's intraday structure, which shows buyers dominated Monday's session. But a conviction score of 20/100 and a grade of D reflect how much technical work remains before this would be considered a quality setup.

Risk flag: A stock down 82.7% from its 52-week high surging 24% in a single session with no confirmed catalyst and a bearish MA stack is a high-risk profile. Volume spikes like this without a durable catalyst often fade quickly, and the existing downtrend can reassert itself.

The bottom line

Monday's biggest gainers were a vivid reminder of how quickly small-cap and micro-cap stocks can move — and how different the risk profiles can be even within a single day's leaderboard. Agenus had a real, reported catalyst (a $340M financing package), which at least gives traders something concrete to evaluate. SOBR and Actuate, by contrast, had no confirmed fundamental driver, making their moves far harder to underwrite with confidence.

Chasing stocks after gains of 24%, 82%, or 174% in a single session is one of the highest-risk moves in trading. Extended gainers often give back a large portion of the move — sometimes the very next morning — as early buyers sell into lingering demand. Short-squeeze and momentum plays are especially prone to violent reversals once the buying pressure fades. Always define your risk before entering any position, size appropriately, and do your own research beyond any single recap or scan.

StockSetups scans the full ~12,300-stock US universe after every close, detecting chart patterns confirmed by candlestick signals and sorting setups by conviction score, short-squeeze score, and smart-money activity — so you can see names like these before the next big move, not after. For more recent action, check out Friday's premarket movers recap or last Thursday's close recap.

This article is for educational and informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security.